Farnesoid X receptor: from medicinal chemistry to clinical applications.
暂无分享,去创建一个
A. Zampella | S. Fiorucci | A. Mencarelli | Stefano Fiorucci | Angela Zampella | Andrea Mencarelli | Elenora Distrutti | E. Distrutti
[1] J. Hardies,et al. A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis. , 2006, The New England journal of medicine.
[2] M. Downes,et al. FXR and PXR: Potential therapeutic targets in cholestasis , 2012, The Journal of Steroid Biochemistry and Molecular Biology.
[3] M. Orešič,et al. Farnesoid X Receptor Deficiency Improves Glucose Homeostasis in Mouse Models of Obesity , 2011, Diabetes.
[4] M. Christian,et al. Metabolic regulation by the nuclear receptor corepressor RIP140 , 2006, Trends in Endocrinology & Metabolism.
[5] F. Moy,et al. The nuclear hormone receptor farnesoid X receptor (FXR) is activated by androsterone. , 2006, Endocrinology.
[6] S. Fiorucci,et al. The Farnesoid X Receptor Promotes Adipocyte Differentiation and Regulates Adipose Cell Function in Vivo , 2006, Molecular Pharmacology.
[7] K. Houck,et al. The Hypolipidemic Natural Product Guggulsterone Is a Promiscuous Steroid Receptor Ligand , 2005, Molecular Pharmacology.
[8] J. W. Becker,et al. Identification of a potent synthetic FXR agonist with an unexpected mode of binding and activation , 2008, Proceedings of the National Academy of Sciences.
[9] K. Houck,et al. T0901317 is a dual LXR/FXR agonist. , 2004, Molecular genetics and metabolism.
[10] S. Mudaliar,et al. A NEW THERAPY FOR NONALCOHOLIC FATTY LIVER DISEASE AND DIABETES? INT-747-THE FIRST FXR HEPATIC THERAPEUTIC STUDY , 2009 .
[11] G. Bifulco,et al. The Bile Acid Receptor GPBAR-1 (TGR5) Modulates Integrity of Intestinal Barrier and Immune Response to Experimental Colitis , 2011, PloS one.
[12] D. Hum,et al. The farnesoid X receptor induces very low density lipoprotein receptor gene expression , 2004, FEBS letters.
[13] G. Bifulco,et al. Theonellasterols and conicasterols from Theonella swinhoei. Novel marine natural ligands for human nuclear receptors. , 2011, Journal of medicinal chemistry.
[14] J. Boyer,et al. The farnesoid X receptor FXRalpha/NR1H4 acquired ligand specificity for bile salts late in vertebrate evolution. , 2007, American journal of physiology. Regulatory, integrative and comparative physiology.
[15] F. Baldelli,et al. Bile acid-activated receptors in the treatment of dyslipidemia and related disorders. , 2010, Progress in lipid research.
[16] E. Distrutti,et al. Antiatherosclerotic effect of farnesoid X receptor. , 2009, American journal of physiology. Heart and circulatory physiology.
[17] T. Willson,et al. Bile acid derivatives as ligands of the farnesoid X receptor. Synthesis, evaluation, and structure-activity relationship of a series of body and side chain modified analogues of chenodeoxycholic acid. , 2004, Journal of medicinal chemistry.
[18] Marco Migliorati,et al. Farnesoid X receptor suppresses constitutive androstane receptor activity at the multidrug resistance protein-4 promoter. , 2011, Biochimica et biophysica acta.
[19] K. Kostner,et al. Farnesoid X receptor represses hepatic human APOA gene expression. , 2011, The Journal of clinical investigation.
[20] R. Evans,et al. Benefit of farnesoid X receptor inhibition in obstructive cholestasis. , 2006, Proceedings of the National Academy of Sciences of the United States of America.
[21] J. Boyer,et al. Mrp4−/− mice have an impaired cytoprotective response in obstructive cholestasis , 2006, Hepatology.
[22] Gabriele Costantino,et al. Farnesoid X receptor: from structure to potential clinical applications. , 2005, Journal of medicinal chemistry.
[23] Songwen Zhang,et al. Abstract 584: A Synthetic Farnesoid X Receptor Agonist Protects Against Diet-Induced Dyslipidemia , 2007 .
[24] G. Bifulco,et al. Discovery That Theonellasterol a Marine Sponge Sterol Is a Highly Selective FXR Antagonist That Protects against Liver Injury in Cholestasis , 2012, PloS one.
[25] E. Distrutti,et al. Targeting farnesoid X receptor for liver and metabolic disorders. , 2007, Trends in molecular medicine.
[26] F. Carrat,et al. The effect of ursodeoxycholic acid therapy on the natural course of primary biliary cirrhosis. , 2005, Gastroenterology.
[27] Jasmine Chen,et al. Endogenous bile acids are ligands for the nuclear receptor FXR/BAR. , 1999, Molecular cell.
[28] D. Hum,et al. Farnesoid X receptor represses hepatic lipase gene expression Published, JLR Papers in Press, September 1, 2004. DOI 10.1194/jlr.M400221-JLR200 , 2004, Journal of Lipid Research.
[29] Giuseppe Bifulco,et al. Discovery of sulfated sterols from marine invertebrates as a new class of marine natural antagonists of farnesoid-X-receptor. , 2011, Journal of medicinal chemistry.
[30] Kazuhide Inoue,et al. The novel compounds that activate farnesoid X receptor: the diversity of their effects on gene expression. , 2008, Journal of pharmacological sciences.
[31] M. Evans,et al. Activation of farnesoid X receptor prevents atherosclerotic lesion formation in LDLR−/− and apoE−/− mice Published, JLR Papers in Press, January 27, 2009. , 2009, Journal of Lipid Research.
[32] Jasmine Chen,et al. Identification of Gene-selective Modulators of the Bile Acid Receptor FXR* , 2003, The Journal of Biological Chemistry.
[33] Jasmine Chen,et al. Identification of a nuclear receptor that is activated by farnesol metabolites , 1995, Cell.
[34] J. Auwerx,et al. Lowering Bile Acid Pool Size with a Synthetic Farnesoid X Receptor (FXR) Agonist Induces Obesity and Diabetes through Reduced Energy Expenditure* , 2011, The Journal of Biological Chemistry.
[35] K. Lindor,et al. 2 FARNESOID-X RECEPTOR AGONISTS: A NEW CLASS OF DRUGS FOR THE TREATMENT OF PBC? AN INTERNATIONAL STUDY EVALUATING THE ADDITION OF INT-747 TO URSODEOXYCHOLIC ACID , 2010 .
[36] Shawn P Williams,et al. Conformationally constrained farnesoid X receptor (FXR) agonists: Naphthoic acid-based analogs of GW 4064. , 2008, Bioorganic & medicinal chemistry letters.
[37] Masahiro Tohkin,et al. Targeted Disruption of the Nuclear Receptor FXR/BAR Impairs Bile Acid and Lipid Homeostasis , 2000, Cell.
[38] G. Farrell,et al. Nonalcoholic fatty liver disease: From steatosis to cirrhosis , 2006, Hepatology.
[39] S. Fiorucci,et al. The bile acid sensor FXR regulates insulin transcription and secretion. , 2010, Biochimica et biophysica acta.
[40] S. Fiorucci,et al. Targetting farnesoid-X-receptor: from medicinal chemistry to disease treatment. , 2010, Current medicinal chemistry.
[41] M. Trauner,et al. Principles of hepatic organic anion transporter regulation during cholestasis, inflammation and liver regeneration. , 2007, Biochimica et biophysica acta.
[42] F. Pattou,et al. The nuclear receptor FXR is expressed in pancreatic β‐cells and protects human islets from lipotoxicity , 2010, FEBS letters.
[43] J. Chiang,et al. Bile acids: regulation of synthesis , 2009, Journal of Lipid Research.